Jonathan Kelly
Medical · Farmington, NMNPI 1053529446
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,101 and has fallen 57.4% since, to $469 in 2025. Among medical clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$381
- AstraZeneca$344
- Astellas Pharma US Inc$335
- Lilly USA, LLC$325
- Biohaven Pharmaceuticals, Inc.$290
- AbbVie$264
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,08797%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 16 | $381 |
| AstraZeneca | 17 | $344 |
| Astellas Pharma US Inc | 11 | $335 |
| Lilly USA, LLC | 16 | $325 |
| Biohaven Pharmaceuticals, Inc. | 7 | $290 |
| AbbVie | 13 | $264 |
| Novo Nordisk | 12 | $203 |
| Pfizer | 10 | $198 |
| Amgen | 5 | $101 |
| Johnson & Johnson | 5 | $97 |
| Merck | 5 | $89 |
| GSK | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Novartis | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Phadia US Inc. | 1 | $50 |
| Insulet Corporation | 2 | $47 |
| Lundbeck LLC | 2 | $46 |
| Exact Sciences | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Dexcom, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$122
How this compares
$3,182 in reported general payments places this provider in the 90th percentile of 156 medical providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 48 | $46,434 |
| JardianceEmpagliflozin | 48 | $40,950 |
| EliquisApixaban | 39 | $40,012 |
| XareltoRivaroxaban | 20 | $23,396 |
| JanuviaSitagliptin Phosphate | 16 | $22,381 |
| RexultiBrexpiprazole | 14 | $19,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,034 |
| OzempicSemaglutide | 13 | $13,978 |
| FarxigaDapagliflozin Propanediol | 12 | $13,832 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $13,404 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $10,509 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,588 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $8,269 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $6,437 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 18 | $5,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $381 | $49,53866 claims |
| Lilly USA, LLCTrulicity | $325 | $46,43448 claims |
| PfizerEliquis | $198 | $40,01239 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $76 | $35,88771 claims |
| Johnson & JohnsonXarelto | $97 | $23,39620 claims |
| MerckJanuvia | $89 | $22,38116 claims |
| AstraZenecaFarxiga, Symbicort | $344 | $22,10140 claims |
| Novo NordiskOzempic | $203 | $13,97813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 156 medical providers in New Mexico.
Other medical in Farmington
- Amy KnackendoffelFarmington$2K
- Stephen SmithFarmington$1K
- Cody LewisFarmington$762
- Rachel MorrFarmington$760
- Brittany FlorenceFarmington$493
- Brenda PachecoAcoma$12K
- Paul TapiaAlbuquerque$7K
- Niki NinopoulosAlbuquerque$7K
- William BaconSanta Fe$6K
- Katie JoshiAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.